OAC
KYTX icon

OMERS Administration Corp’s Kyverna Therapeutics KYTX Stock Holding History

OMERS Administration Corp’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Sell
14,800
-20,000
-57% -$167K ﹤0.01% 982
2025
Q4 		$327K Buy
+34,800
New +$258K ﹤0.01% 787

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

OMERS Administration Corp's KYTX Position: Q1 2026 in Review

OMERS Administration Corp reduced its Kyverna Therapeutics (KYTX) stake by 57% in Q1 2026, selling an estimated $167K and leaving 14,800 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

OMERS Administration Corp first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $327K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • OMERS Administration Corp held 14,800 shares of Kyverna Therapeutics worth $128K as of Q1 2026.
  • OMERS Administration Corp sold 20,000 Kyverna Therapeutics shares in Q1 2026, an estimated $167K.
  • Kyverna Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #982 holding.
  • OMERS Administration Corp first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Kyverna Therapeutics position peaked at $327K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.